Madrigal Pharmaceuticals (MDGL) News Today $317.09 +2.92 (+0.93%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Connor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Connor Clark & Lunn Investment Management Ltd. reduced its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,083 shares of thNovember 21 at 5:44 AM | marketbeat.comMadrigal Pharmaceuticals price target raised to $400 from $350 at OppenheimerNovember 21 at 4:11 AM | markets.businessinsider.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from TD CowenNovember 20 at 11:59 AM | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday.November 20 at 9:05 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two hNovember 18 at 1:31 AM | marketbeat.comMadrigal Pharmaceuticals gains amid takeover speculationNovember 15, 2024 | msn.com1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or MoreNovember 10, 2024 | fool.comMadrigal Pharmaceuticals Engages with Investors at Key ConferencesNovember 9, 2024 | msn.comFiera Capital Corp Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Fiera Capital Corp cut its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,880 shares of the biopharmaceutical comNovember 9, 2024 | marketbeat.comB. Riley Has Positive Estimate for MDGL FY2024 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at B. Riley boosted their FY2024 earnings estimates for Madrigal Pharmaceuticals in a report issued on Monday, November 4th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($23.09) per sharNovember 7, 2024 | marketbeat.comMadrigal Pharmaceuticals price target raised to $236 from $194 at B. RileyNovember 6, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comEquities Analysts Issue Forecasts for MDGL Q1 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - B. Riley issued their Q1 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a report released on Monday, November 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings per share of ($November 6, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $1,504,700.00 in StockNovember 6, 2024 | insidertrades.comB. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) StockB. Riley raised their target price on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a "neutral" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comMadrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes ExpectationsNovember 4, 2024 | finance.yahoo.comJefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)November 4, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst UpgradeMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst UpgradeNovember 4, 2024 | marketbeat.comEmerald Advisers LLC Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Emerald Advisers LLC trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 71.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,265 shares of the biopharmaceuticaNovember 4, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for MDGL FY2028 Earnings?Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Thursday, October 31st. Leerink Partnrs analyst T. Smith now expects that the biopharmaceuticNovember 4, 2024 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)November 3, 2024 | markets.businessinsider.comAnalysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ForecastsNovember 3, 2024 | finance.yahoo.comRezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European ExpansionNovember 3, 2024 | seekingalpha.comMadrigal Pharmaceuticals stock jumps on MASH drug hopesNovember 1, 2024 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comOppenheimer Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)November 1, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS GroupUBS Group raised their price target on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a "buy" rating in a report on Friday.November 1, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPSMadrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, beating the consensus estimate of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to the consensus estimate of $34.60 million. During the same quarter last year, the firm earned ($5.34) EPS.November 1, 2024 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong EarningsMadrigal Pharmaceuticals (NASDAQ:MDGL) Sees Unusually-High Trading Volume Following Better-Than-Expected EarningsNovember 1, 2024 | marketbeat.comMadrigal Pharmaceuticals Reports Strong Rezdiffra LaunchNovember 1, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...November 1, 2024 | finance.yahoo.comMadrigal Pharmaceuticals price target raised to $394 from $377 at CanaccordOctober 31, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals: Surpassing Revenue Expectations and Expanding Market Reach Justifies Buy RatingOctober 31, 2024 | markets.businessinsider.comMontgomery County firm's shares soar on huge sales increase of flagship drugOctober 31, 2024 | bizjournals.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up - Should You Buy?Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up - Time to Buy?October 31, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 31, 2024 | seekingalpha.comMadrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate UpdatesOctober 31, 2024 | markets.businessinsider.comEarnings Preview For Madrigal PharmaceuticalsOctober 30, 2024 | benzinga.comMadrigal Pharmaceuticals to present multiple resmetirom data presentationsOctober 30, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®October 30, 2024 | globenewswire.comBank of America Securities Sticks to Their Sell Rating for Madrigal Pharmaceuticals (MDGL)October 29, 2024 | markets.businessinsider.comBank of America Securities Sticks to Their Sell Rating for Madrigal Pharmaceuticals (MDGL)October 29, 2024 | markets.businessinsider.comCavalier Investments LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Cavalier Investments LLC bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,641 shares of the biopharmaceutOctober 28, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 5,915 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Mirae Asset Global Investments Co. Ltd. cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 76,822 shares of the biopharmaceutical company's stoOctober 27, 2024 | marketbeat.comEvercore ISI Remains a Buy on Madrigal Pharmaceuticals (MDGL)October 25, 2024 | markets.businessinsider.comMadrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 EarningsOctober 24, 2024 | seekingalpha.comMadrigal Pharmaceuticals (MDGL) to Release Earnings on ThursdayMadrigal Pharmaceuticals (NASDAQ:MDGL) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637262)October 24, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of "Moderate Buy" by AnalystsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recOctober 24, 2024 | marketbeat.comMadrigal Pharmaceuticals price target lowered to $350 from $375 at OppenheimerOctober 24, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES TrialOctober 24, 2024 | msn.com Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. MDGL Media Mentions By Week MDGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼0.900.45▲Average Medical News Sentiment MDGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼57▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rocket Pharmaceuticals News Today Y-mAbs Therapeutics News Today Generation Bio News Today Biogen News Today United Therapeutics News Today Incyte News Today Neurocrine Biosciences News Today BioMarin Pharmaceutical News Today Exelixis News Today Exact Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
